Free Trial

Landscape Capital Management L.L.C. Takes Position in DocuSign, Inc. (NASDAQ:DOCU)

DocuSign logo with Computer and Technology background
Remove Ads

Landscape Capital Management L.L.C. purchased a new position in DocuSign, Inc. (NASDAQ:DOCU - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,502 shares of the company's stock, valued at approximately $2,294,000.

Several other institutional investors and hedge funds have also bought and sold shares of DOCU. Kestra Investment Management LLC bought a new position in shares of DocuSign in the 4th quarter worth approximately $30,000. First Horizon Advisors Inc. lifted its stake in DocuSign by 102.6% during the 4th quarter. First Horizon Advisors Inc. now owns 397 shares of the company's stock valued at $36,000 after acquiring an additional 201 shares during the period. Modus Advisors LLC purchased a new stake in DocuSign in the fourth quarter worth approximately $36,000. Avion Wealth increased its position in DocuSign by 309.2% during the fourth quarter. Avion Wealth now owns 487 shares of the company's stock valued at $43,000 after acquiring an additional 368 shares during the last quarter. Finally, Avior Wealth Management LLC boosted its holdings in shares of DocuSign by 36.5% in the fourth quarter. Avior Wealth Management LLC now owns 542 shares of the company's stock worth $49,000 after buying an additional 145 shares during the last quarter. 77.64% of the stock is currently owned by institutional investors.

DocuSign Price Performance

DOCU traded down $0.26 on Monday, reaching $71.95. 4,106,032 shares of the company traded hands, compared to its average volume of 2,706,123. DocuSign, Inc. has a 52-week low of $48.70 and a 52-week high of $107.86. The stock's 50 day moving average price is $86.02 and its 200-day moving average price is $82.35. The company has a market cap of $14.57 billion, a price-to-earnings ratio of 14.84, a PEG ratio of 6.94 and a beta of 1.20.

Remove Ads

DocuSign (NASDAQ:DOCU - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.02. DocuSign had a return on equity of 14.90% and a net margin of 34.73%. The business had revenue of $776.25 million for the quarter, compared to analyst estimates of $760.94 million. During the same period in the previous year, the company posted $0.76 earnings per share. The firm's revenue for the quarter was up 9.0% on a year-over-year basis. As a group, equities research analysts forecast that DocuSign, Inc. will post 1.17 earnings per share for the current fiscal year.

Insider Activity at DocuSign

In other DocuSign news, Director Teresa Briggs sold 534 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $87.41, for a total transaction of $46,676.94. Following the sale, the director now directly owns 8,270 shares of the company's stock, valued at $722,880.70. The trade was a 6.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider James P. Shaughnessy sold 7,500 shares of the company's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $81.31, for a total transaction of $609,825.00. Following the completion of the sale, the insider now directly owns 45,875 shares in the company, valued at approximately $3,730,096.25. The trade was a 14.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,851 shares of company stock valued at $4,911,319 over the last ninety days. 1.66% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DOCU. UBS Group decreased their price target on shares of DocuSign from $100.00 to $90.00 and set a "neutral" rating on the stock in a research note on Friday, March 14th. Jefferies Financial Group reduced their target price on shares of DocuSign from $115.00 to $105.00 and set a "buy" rating on the stock in a research report on Monday, March 31st. Needham & Company LLC reissued a "hold" rating on shares of DocuSign in a research report on Friday, March 14th. Citigroup upped their price objective on DocuSign from $113.00 to $115.00 and gave the stock a "buy" rating in a research note on Friday, March 14th. Finally, Bank of America decreased their price objective on DocuSign from $112.00 to $98.00 and set a "neutral" rating for the company in a report on Friday, March 14th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, DocuSign currently has an average rating of "Hold" and an average price target of $95.83.

Get Our Latest Report on DocuSign

About DocuSign

(Free Report)

DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.

See Also

Institutional Ownership by Quarter for DocuSign (NASDAQ:DOCU)

Should You Invest $1,000 in DocuSign Right Now?

Before you consider DocuSign, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocuSign wasn't on the list.

While DocuSign currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

5 Big Reasons the S&P 500 Could Soar in 2025
3 Stocks to Buy on the Dip—and 3 to Dump Fast
Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads